Study Points to New Target for Cancers Resistant to Certain Drugs
Published: Tuesday, September 11, 2012 Last Updated: Tuesday, September 11, 2012
A more sensitive method to analyze protein interactions has uncovered a new way that cancer cells may use the cell-surface molecule HER3 to drive tumor progression following treatment with HER1 and HER2 inhibitors.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.